PharmiWeb.com - Global Pharma News & Resources
20-Sep-2019

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

SMI Reports: Exclusive interview with industry expert, Richard Arnett Manager, Industrial Hygiene, Pharmascience for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October. 

Snapshot of Richard’s Interview: 

What key differences have you noticed in the last year regarding significant developments in Highly Potent APIs?
“Three main points: Higher potency, particularly for OSD products Lower ADE, often poorly soluble and tougher to clean APIs Closer scrutiny by regulatory agencies. For example Health Canada is now more closely aligned with the EMA and there’s now a more harmonised approach, with a mutual recognition agreement in place which sets the bar to the appropriate level, not just with the regs/GMP’s, but also through compliance/enforcement ensuring that the appropriate controls are in place to mitigate cross-contamination risks…”

What do you see as the greatest challenge for you to overcome personally in the Highly Potent API field currently?
“Changing the culture from traditional ‘open processes’ to closed processing with reduced reliance on PPE & thus reduced worker-product exposure risk. I often hear ‘what’s the risk – the workers are wearing respirators’– and there remains a perception that this is adequate… But what about when the airborne concentration might exceed the assigned protection factor of the respirators? Or what about the exposure risk when the respirators are removed?...”

Richard will be joined at the conference by a number of key figures in the HPAPI industry including Rakesh Dixit, Vice President of R&D Global Head, MedImmune; Vice President of R&D Translational Sciences – Biologics Safety Assessment, AstraZeneca; Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants USA and many more.

For the full speaker interview, event details and speaker line-up, visit www.hpapi-usa.com/PR6 

Proudly Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants 

Highly Potent Active Pharmaceutical Ingredients USA
Conference: October 21st – 22nd
Workshops: October 23rd 
Venue: Sheraton Boston Hotel, USA

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk 

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 or nhoward@smi-online.co.uk

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

Editor Details

Related Links

Last Updated: 23-Sep-2019